Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p>Venus Medtech, a China Hangzhou-based transcatheter heart valve medical device player, is looking to raise up to USD 300 million via a listing in Hong Kong.</p>
<p>In our previous insight, we looked at the company's commercial product, VenusA-Valve, and pipeline products, VenusA-Plus and VenusP-Valve. We like the company's strong leadership in the market, its experienced management team and a strong line-up of pre-IPO investors. </p>
<p>In this insight, we will analyse the competitiveness of its VenusA-Valve product by comparing it to global peers and China peers. We also note that Microport's VitaFlow-Valve could become a key contender for the dominance of VenusA-Valve.</p>
<hr>
<h2>Our previous coverage on Venus Medtech</h2>
<ul>
<li><a href="https://www.smartkarma.com/insights/venus-medtech-ipo-has-the-elements-for-a-hot-healthcare-deal" target="_blank" rel="noopener">Venus Medtech (启明医疗) IPO: Has the Elements for a Hot Healthcare Deal</a></li>
</ul>

Venus Medtech, a China Hangzhou-based transcatheter heart valve medical device player, is looking to raise up to USD 300 million via a listing in Hong Kong.
In our previous insight, we looked at the company's commercial product, VenusA-Valve, and pipeline products, VenusA-Plus and VenusP-Valve. We like the company's strong leadership in the market, its experienced management team and a strong line-up of pre-IPO investors. 
In this insight, we will analyse the competitiveness of its VenusA-Valve product by comparing it to global peers and China peers. We also note that Microport's VitaFlow-Valve could become a key contender for the dominance of VenusA-Valve.

Our previous coverage on Venus Medtech

Venus Medtech (启明医疗) IPO: Has the Elements for a Hot Healthcare Deal


Venus Medtech (启明医疗) IPO: Technical Comparison of VenusA-Valve and Peers

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

<p><a href="https://www.smartkarma.com/entities/venus-medtech-hangzhou-inc" target="_blank" data-smartkarma-citation="entities:28257:1" rel="noopener">Venus MedTech Hangzhou Inc (1392140D CH)</a> is a leading transcatheter heart valve medical device company in China. VenusA-Valve, a self-developed product, was launched in August 2017 and is the first TAVR (transcatheter aortic heart valve replacement) product to be commercialised in China. According to a Bloomberg article in August 2018, Venus is seeking to raise $300-500 million.</p><div class="content-highlight"><p>Although Venus falls under HKEX’s definition of a biotech company, it generates meaningful revenue from VenusA-Valve. With a large addressable market opportunity and first-mover advantage in China, we believe that Venus’s fundamentals are heading in the right direction</p></div>

Venus MedTech Hangzhou Inc (1392140D CH) is a leading transcatheter heart valve medical device company in China. VenusA-Valve, a self-developed product, was launched in August 2017 and is the first TAVR (transcatheter aortic heart valve replacement) product to be commercialised in China. According to a Bloomberg article in August 2018, Venus is seeking to raise $300-500 million.Although Venus falls under HKEX’s definition of a biotech company, it generates meaningful revenue from VenusA-Valve. With a large addressable market opportunity and first-mover advantage in China, we believe that Venus’s fundamentals are heading in the right direction

Venus Medtech IPO Initiation: The Heart of the Business

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>The S&amp;P 500 is consolidating under 2,954 - logical resistance - as market participants are in wait-and-see mode for incremental trade news ahead of the Trump/Xi G20 meeting later this week. While a breakout is certainly possible, we believe additional consolidation is the more likely scenario. In today's report we highlight a mix of positive and negative developments which lead us to this conclusion along with updates on other big picture trends. Also highlighted are attractive Groups and stocks within Materials, Health Care, and Utilities: Gold, Western Hemisphere, Cardiovascular Products, and Gas, Midwest.</p>

The S&amp;P 500 is consolidating under 2,954 - logical resistance - as market participants are in wait-and-see mode for incremental trade news ahead of the Trump/Xi G20 meeting later this week. While a breakout is certainly possible, we believe additional consolidation is the more likely scenario. In today's report we highlight a mix of positive and negative developments which lead us to this conclusion along with updates on other big picture trends. Also highlighted are attractive Groups and stocks within Materials, Health Care, and Utilities: Gold, Western Hemisphere, Cardiovascular Products, and Gas, Midwest.

U.S. Dollar Breaking Down; Gold Breaking Out

Nasdaq-100 Stock Index / Technical Analysis

<p>In this report we detail our U.S. investment thesis and provide a detailed technical appraisal of the broad market, as well as highlighting attractive investment opportunities within each of our 12 Sectors.</p>

In this report we detail our U.S. investment thesis and provide a detailed technical appraisal of the broad market, as well as highlighting attractive investment opportunities within each of our 12 Sectors.

U.S. Equity Strategy: Defensive Areas Weakening; Broad Market Attempting to Bottom

<ul><li><strong>U.S. equity markets remain resilient. </strong>Led by strength in technology and biotech, the Nasdaq hit a new all-time high yesterday. Small-cap indexes are also hitting all-time highs. Moreover, the S&amp;P 500 has moved to a new high relative to May prices, providing new evidence that the market is likely to continue its trend higher. Given these developments, our outlook continues to move toward the bullish camp. In today’s report we highlight attractive and actionable stocks within Energy (Refiners) and Health Care (Cardiovascular Products, and Surgical Devices &amp; Equipment).</li></ul>

U.S. equity markets remain resilient. Led by strength in technology and biotech, the Nasdaq hit a new all-time high yesterday. Small-cap indexes are also hitting all-time highs. Moreover, the S&amp;P 500 has moved to a new high relative to May prices, providing new evidence that the market is likely to continue its trend higher. Given these developments, our outlook continues to move toward the bullish camp. In today’s report we highlight attractive and actionable stocks within Energy (Refiners) and Health Care (Cardiovascular Products, and Surgical Devices &amp; Equipment).

U.S. Equity Strategy: Opportunities in Refiners & Med Device Makers

United States

Edwards Lifesciences Corporation designs, develops, manufactures, and markets products and services to treat late-stage cardiovascular disease.  The Company's products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals.  Edwards supplies its products to customers located worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Edwards Lifesciences (EW US)

Venus Medtech (启明医疗) IPO: Technical Comparison of VenusA-Valve and Peers

Venus Medtech, a China Hangzhou-based transcatheter heart valve medical device player, is looking to raise up to USD 300 million via a listing in...

Ke Yan, CFA, FRM

Venus Medtech IPO Initiation: The Heart of the Business

Venus MedTech Hangzhou Inc (1392140D CH) is a leading transcatheter heart valve medical device company in China. VenusA-Valve, a self-developed...

Arun George

U.S. Dollar Breaking Down; Gold Breaking Out

The S&P 500 is consolidating under 2,954 - logical resistance - as market participants are in wait-and-see mode for incremental trade news...

Vermilion Research

U.S. Equity Strategy: Defensive Areas Weakening; Broad Market Attempting to Bottom

In this report we detail our U.S. investment thesis and provide a detailed technical appraisal of the broad market, as well as highlighting...

Vermilion Research

U.S. Equity Strategy: Opportunities in Refiners & Med Device Makers

U.S. equity markets remain resilient. Led by strength in technology and biotech, the Nasdaq hit a new all-time high yesterday. Small-cap indexes...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)